Cellular and molecular mechanisms of chronic obstructive pulmonary disease

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 71-86

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Autoantibody; Chemokine; Cytokine; Inflammation; Macrophage; Neutrophil; Nuclear factor B; Oxidative stress

Indexed keywords

AUTOANTIBODY; CHEMOKINE; CYTOKINE; INFLAMMATION; MACROPHAGE; NEUTROPHIL; NUCLEAR FACTOR-ΚB; OXIDATIVE STRESS;

HUMANS; INFLAMMATION; LUNG; LUNG NEOPLASMS; MACROPHAGES, ALVEOLAR; NEUTROPHILS; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84893771777     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.10.004     Document Type: Review

References (124)

1. Barnes P.J. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010, 7:e1000220.
2. Barnes P.J. New anti-inflammatory treatments for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013, 12(7):543-559.
3. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009, 374:733-743.
4. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. NEngl J Med 2004, 350:2645-2653.
5. McDonough J.E., Yuan R., Suzuki M., et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. NEngl J Med 2011, 365:1567-1575.
6. Galban C.J., Han M.K., Boes J.L., et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 2012, 18:1711-1715.
7. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8:183-192.
8. Cosio M.G., Saetta M., Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. NEngl J Med 2009, 360:2445-2454.
9. Brusselle G.G., Joos G.F., Bracke K.R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011, 378:1015-1026.
10. Van Pottelberge G.R., Bracke K.R., Joos G.F., et al. The role of dendritic cells in the pathogenesis of COPD: liaison officers in the front line. COPD 2009, 6:284-290.
11. Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004, 56:515-548.
12. Donnelly L.E., Barnes P.J. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006, 27:546-553.
13. Gamble E., Grootendorst D.C., Hattotuwa K., et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007, 30:467-471.
14. Petrache I., Natarajan V., Zhen L., et al. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005, 11:491-498.
15. de Boer W.I., Hau C.M., van Schadewijk A., et al. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 2006, 125:184-192.
16. Barnes P.J. Macrophages as orchestrators of COPD. COPD 2004, 1:59-70.
17. Meshi B., Vitalis T.Z., Ionescu D., et al. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 2002, 26:52-57.
18. Russell R.E., Thorley A., Culpitt S.V., et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002, 283:L867-L873.
19. Gordon S., Pluddemann A. Tissue macrophage heterogeneity: issues and prospects. Semin Immunopathol 2013, 35(5):533-540.
20. Caramori G., Romagnoli M., Casolari P., et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 2003, 58:348-351.
21. Traves S.L., Culpitt S., Russell R.E., et al. Elevated levels of the chemokines GRO-alpha and MCP-1 in sputum samples from COPD patients. Thorax 2002, 57:590-595.
22. Traves S.L., Smith S.J., Barnes P.J., et al. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. JLeukoc Biol 2004, 76:441-450.
23. Grumelli S., Corry D.B., Song L.X., et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004, 1:75-83.
24. Culpitt S.V., Rogers D.F., Shah P., et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:24-31.
25. Keatings V.M., Jatakanon A., Worsdell Y.M., et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155:542-548.
26. Ito K., Ito M., Elliott W.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. NEngl J Med 2005, 352:1967-1976.
27. Ito K., Yamamura S., Essilfie-Quaye S., et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. JExp Med 2006, 203:7-13.
28. Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009, 71:451-464.
29. Taylor A.E., Finney-Hayward T.K., Quint J.K., et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 2010, 35:1039-1047.
30. Hodge S., Hodge G., Scicchitano R., et al. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003, 81:289-296.
31. Donnelly L.E., Barnes P.J. Defective phagocytosis in airways disease. Chest 2012, 141:1055-1062.
32. Mullerova H., Chigbo C., Hagan G.W., et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012, 106:1124-1133.
33. Keatings V.M., Collins P.D., Scott D.M., et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153:530-534.
34. Keatings V.M., Barnes P.J. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir Crit Care Med 1997, 155:449-453.
35. Biernacki W.A., Kharitonov S.A., Barnes P.J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003, 58:294-298.
36. Aaron S.D., Angel J.B., Lunau M., et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:349-355.
37. Sapey E., Stockley J.A., Greenwood H., et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183:1176-1186.
38. Traves S.L., Smith S.J., Barnes P.J., et al. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 2004, 76:441-450.
39. Turato G., Zuin R., Saetta M. Pathogenesis and pathology of COPD. Respiration 2001, 68:117-128.
40. Brightling C.E., Monteiro W., Ward R., et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-1485.
41. Papi A., Romagnoli M., Baraldo S., et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1773-1777.
42. Saetta M., Distefano A., Maestrelli P., et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994, 150:1646-1652.
43. Saetta M., Di Stefano A., Maestrelli P., et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996, 26:766-774.
44. Zhu J., Qiu Y.S., Majumdar S., et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001, 164:109-116.
45. Liu H., Lazarus S.C., Caughey G.H., et al. Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils invitro. Am J Physiol 1999, 276:L28-L34.
46. Van Pottelberge G.R., Bracke K.R., Demedts I.K., et al. Selective accumulation of Langerhans-type dendritic cells in small airways of patients with COPD. Respir Res 2010, 11:35.
47. Freeman C.M., Martinez F.J., Han M.K., et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:1179-1188.
48. Di Stefano A., Caramori G., Capelli A., et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J 2004, 24:78-85.
49. Di Stefano A., Caramori G., Gnemmi I., et al. Thelper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 2009, 157:316-324.
50. Pridgeon C., Bugeon L., Donnelly L., et al. Regulation of IL-17 in chronic inflammation in the human lung. Clin Sci (Lond) 2011, 120:515-524.
51. Costa C., Rufino R., Traves S.L., et al. CXCR3 and CCR5 chemokines in the induced sputum from patients with COPD. Chest 2008, 133:26-33.
52. Saetta M., Mariani M., Panina-Bordignon P., et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165:1404-1409.
53. Kirkham P.A., Caramori G., Casolari P., et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:796-802.
54. Karayama M., Inui N., Suda T., et al. Antiendothelial cell antibodies in patients with COPD. Chest 2010, 138:1303-1308.
55. Majo J., Ghezzo H., Cosio M.G. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001, 17:946-953.
56. Lambers C., Hacker S., Posch M., et al. Tcell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2009, 155:466-475.
57. Hodge G., Mukaro V., Reynolds P.N., et al. Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin Exp Immunol 2011, 166:94-102.
58. Montuschi P., Kharitonov S.A., Ciabattoni G., et al. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003, 58:585-588.
59. Beeh K.M., Kornmann O., Buhl R., et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003, 123:1240-1247.
60. Barnes P.J. Cytokine networks in asthma and chronic obstructive pulmonary disease. JClin Invest 2008, 118:3546-3556.
61. Barnes P.J. The cytokine network in COPD. Am J Respir Cell Mol Biol 2009, 41:631-638.
62. Birrell M.A., Eltom S. The role of the NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol Ther 2011, 130:364-370.
63. Doe C., Bafadhel M., Siddiqui S., et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 2010, 138:1140-1147.
64. Fahy J.V., Dickey B.F. Airway mucus function and dysfunction. NEngl J Med 2010, 363:2233-2247.
65. Tuder R.M., Yoshida T., Arap W., et al. State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc 2006, 3:503-510.
66. O'Reilly P., Jackson P.L., Noerager B., et al. N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. Respir Res 2009, 10:38.
67. Kirkham P.A., Barnes P.J. Oxidative stress in COPD. Chest 2013, 144(1):266-273.
68. Montuschi P., Barnes P.J., Roberts L.J. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004, 18:1791-1800.
69. Osoata G.O., Hanazawa T., Brindicci C., et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009, 135:1513-1520.
70. Brindicci C., Kharitonov S.A., Ito M., et al. Nitric oxide synthase isoenzyme expression and activity in peripheral lungs of COPD patients. Am J Respir Crit Care Med 2010, 181:21-30.
71. Malhotra D., Thimmulappa R., Navas-Acien A., et al. Decline in NRF2 regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1. Am J Respir Crit Care Med 2008, 178:592-604.
72. Malhotra D., Thimmulappa R.K., Mercado N., et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. JClin Invest 2011, 121(11):4289-4302.
73. Mercado N., Thimmulappa R., Thomas C.M., et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun 2011, 406:292-298.
74. Tomita K., Barnes P.J., Adcock I.M. The effect of oxidative stress on histone acetylation and IL-8 release. Biochem Biophys Res Commun 2003, 301:572-577.
75. Nakamaru Y., Vuppusetty C., Wada H., et al. Aprotein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009, 23:2810-2819.
76. Adcock I.M., Caramori G., Barnes P.J. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011, 81:265-284.
77. Rahman I., Morrison D., Donaldson K., et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996, 154:1055-1060.
78. Groenewegen K.H., Postma D.S., Hop W.C., et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133:350-357.
79. Gan W.Q., Man S.F., Senthilselvan A., et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
80. van Eeden S.F., Sin D.D. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008, 75:224-238.
81. Thomsen M., Dahl M., Lange P., et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186(10):982-988.
82. Agusti A., Edwards L.D., Rennard S.I., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7:e37483.
83. Hurst J.R., Donaldson G.C., Perea W.R., et al. Utility of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867-874.
84. Dahl M., Vestbo J., Lange P., et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255.
85. de Torres J.P., Pinto-Plata V., Casanova C., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133:1336-1343.
86. Fogarty A.W., Jones S., Britton J.R., et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007, 62:515-520.
87. Perera W.R., Hurst J.R., Wilkinson T.M., et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29:527-534.
88. Donaldson G.C., Seemungal T.A., Patel I.S., et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005, 128:1995-2004.
89. Dahl M., Tybjaerg-Hansen A., Vestbo J., et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1008-1011.
90. Bozinovski S., Hutchinson A., Thompson M., et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:269-278.
91. Bozinovski S., Uddin M., Vlahos R., et al. Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 2012, 109:935-940.
92. Cheng N., He R., Tian J., et al. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. JImmunol 2008, 181:22-26.
93. Sukkar M.B., Wood L.G., Tooze M., et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012, 39:721-729.
94. Sin D.D., Leung R., Gan W.Q., et al. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007, 7:13.
95. Winkler C., Atochina-Vasserman E.N., Holz O., et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res 2011, 12:29.
96. Bhowmik A., Seemungal T.A., Sapsford R.J., et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55(2):114-120.
97. Yende S., Waterer G.W., Tolley E.A., et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006, 61:10-16.
98. Janssen S.P., Gayan-Ramirez G., Van den B.A., et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005, 111:996-1005.
99. Broekhuizen R., Grimble R.F., Howell W.M., et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism. Am J Clin Nutr 2005, 82:1059-1064.
100. de Godoy I., Donahoe M., Calhoun W.J., et al. Elevated TNF-alpha production by peripheral blood monocytes of weight- losing COPD patients. Am J Respir Crit Care Med 1996, 153:633-637.
101. Takabatake N., Nakamura H., Abe S., et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1179-1184.
102. Tracey K.J., Wei H., Manogue K.R., et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. JExp Med 1988, 167:1211-1227.
103. Spruit M.A., Gosselink R., Troosters T., et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003, 58:752-756.
104. Serhan C.N. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?. Am J Pathol 2010, 177:1576-1591.
105. Serhan C.N., Yang R., Martinod K., et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. JExp Med 2009, 206:15-23.
106. Ito K., Barnes P.J. COPD as a disease of accelerated lung aging. Chest 2009, 135:173-180.
107. Culpitt S.V., Rogers D.F., Fenwick P.S., et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003, 58:942-946.
108. Donnelly L.E., Newton R., Kennedy G.E., et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 2004, 287(4):L774-L783.
109. Sharp Z.D. Aging and TOR: interwoven in the fabric of life. Cell Mol Life Sci 2011, 68:587-597.
110. Amsellem V., Gary-Bobo G., Marcos E., et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:1358-1366.
111. de Boer W.I., van Schadewijk A., Sont J.K., et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:1951-1957.
112. Sime P.J. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. JInvestig Med 2008, 56:534-538.
113. Fonseca C., Abraham D., Renzoni E.A. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011, 44:1-10.
114. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 342:1905-1917.
115. Cosio B.G., Tsaprouni L., Ito K., et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. JExp Med 2004, 200:689-695.
116. To Y., Ito K., Kizawa Y., et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in COPD. Am J Respir Crit Care Med 2010, 182:897-904.
117. Ford P.A., Durham A.L., Russell R.E., et al. Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010, 137:1338-1344.
118. Mercado N., To Y., Ito K., et al. Nortriptyline reverses corticosteroid insensitivity by inhibition of PI3K-δ. JPharmacol Exp Ther 2011, 337:465-470.
119. Meja K.K., Rajendrasozhan S., Adenuga D., et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 2008, 39:312-323.
120. Kobayashi Y., Wada H., Rossios C., et al. Anovel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013, 169:1024-1034.
121. Chong J., Poole P., Leung B., et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, (5). CD002309.
122. Barnes P.J., Chowdhury B., Kharitonov S.A., et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:6-14.
123. Rennard S.I., Calverley P.M., Goehring U.M., et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18.
124. Hansel T.T., Barnes P.J. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009, 374:744-755.